Applying Mysimba in patients with weight regain after bariatric surgery

Prior treatment

• Anatomical or surgical abnormalities for which revisional surgery is indicated.
• Patients with excessive use of alcohol or drugs

Other illness

• Use of the following medication Monoamino-oxidase inhibitors (MAO), selective serotonin reuptake inhibitor (SSRI), Tricyclic antidepressants (TCA), haloperidol, risperidone, opioids, antiarrhythmics, betablockers, antiviral medication (HIV)
• Patients suffering from: o unregulated hypertension o a tumour in the central nervous system o severe liver failure o end stage kidney failure
• Patients suffering from or with a history of insults
• Patients with a history of: o bipolar disease o bulimia or anorexia nervosa

Other

• Pregnancy or breastfeeding
• Patients withdrawing from alcohol or benzodiazepines
• Patients who are not able to understand the informed consent form and patient information.

• Patient is ≥18 and <75 years old
• BMI before surgery was ≥ 35.0 kg/m2
• Patient has undergone a primary banded/non-banded Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG)
• Gaining more than 5% weight after reaching plateau phase of lowest weight To be eligible to participate in the control patient cohort for measuring bupropion and hydroxybupropion serum levels a subject must meet all of the following criteria: • Patient is ≥18 and <75 years old • Patient is obese (BMI > 30 kg/m2) • Patient on successful Mysimba steady maintenance dose